ADMA Biologics (ADMA) Misses Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
Go back to ADMA Biologics (ADMA) Misses Q3 EPS by 9c
November 10, 2015 4:53 PM EST
RAMSEY, N.J., Nov. 10, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced its financial results for the third quarter ended September 30, 2015 and provided a corporate update and anticipated upcoming milestones.
ADMA achieved a number of significant, value-creating milestones, during the third quarter. We submitted our Biologics License Application (BLA) seeking marketing approval for RI-002 to the U.S. Food and Drug Administration (FDA), which the FDA... More
November 10, 2015 4:53 PM EST
RAMSEY, N.J., Nov. 10, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced its financial results for the third quarter ended September 30, 2015 and provided a corporate update and anticipated upcoming milestones.
ADMA achieved a number of significant, value-creating milestones, during the third quarter. We submitted our Biologics License Application (BLA) seeking marketing approval for RI-002 to the U.S. Food and Drug Administration (FDA), which the FDA... More
